WISE has raised €30m ($34.8m) to advance the development of its spinal cord stimulation (SCS) device for chronic pain treatment.
The final close of the Italian company’s oversubscribed Series D financing round saw participation from ENEA Tech and Biomedical, along with existing investors. Alongside Biomedical’s capital commitment, the Italian foundation that focuses on innovation and technology transfer in the biomedical sector, will now also serve as a strategic partner to Wise.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Wise, which develops a range of neurology medical devices, said the latest financing follows the company’s initial €25m Series D raise in June 2024 that also included a venture debt loan from the European Investment Bank (EIB). The overall Series D tranche will fund the ongoing development of its lead product, Heron lead SCS device.
Heron lead has been designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique that is facilitated by a combination of the therapeutic surgical paddle and cylindrical leads.
According to Wise, combining these lead types should result in benefits for Heron including higher energy efficiency and improved neural signal sensing.
Wise CEO, Luca Varagnan, commented: “With the Heron lead, we are targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need. This financing gives us the resources to complete the journey from bench to bedside.”
Beyond supporting Heron regulatory certification pathway and a first-in-human study, Wise said a portion of the proceeds would also go towards advancing its electrode portfolio across select target markets.
A key electrode in Wise’s existing product lineup is the WISE Cortical Strip (WCS), designed for neurophysiological monitoring during brain tumour and epilepsy surgeries. The soft electrode obtained US Food and Drug Administration (FDA) clearance in 2022 and a CE mark under the European Union’s Medical Device Regulation (EU MDR) in July 2025.
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation above $24.2bn in 2035, with SCS representing one of the biggest growth segments within the broader market. A GlobalData market model reveals that Medtronic held the largest share of the rechargeable SCS market in the US in 2025 at 29.8%.
